MONTREAL, QUEBEC -- (MARKET WIRE) -- May 24, 2007 -- MethylGene Inc. (TSX: MYG), today announced preliminary preclinical results for its histone deacetylase (HDAC) clinical candidate MGCD290 at the 107th General Meeting of the American Society for Microbiology (ASM).
